KF 17837Alternative Names: KF 17837S
Latest Information Update: 12 Jan 2001
At a glance
- Originator Kyowa Hakko
- Class Antidepressants; Antiepileptic drugs; Antiparkinsonians; Neuroprotectants; Small molecules; Xanthines
- Mechanism of Action Adenosine A2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Parkinson's disease